Michael Tusche

Michael Tusche is the Co-CEO of Treadwell Therapeutics. Michael has over 20 years of experience in the pharmaceutical and biotech industry.

Tusche started their career at Bayer Yakuhin, Ltd. as a Scientist in Asthma Drug Discovery. Michael then moved to University Health Network, where they spent four years as a Post Doctoral Fellow and Director - Autoimmune and Inflammatory Drug Discovery. In 2013, Tusche left University Health Network to join MLV & Co as an Associate in the Life Sciences group.

In 2014, Tusche joined Mountain Brook Capital as a Senior Healthcare Analyst. Michael spent five years at Mountain Brook before co-founding Nirsum Labs in April 2017, where they served as Chief Scientific Officer until December 2019.

Tusche has been with Treadwell Therapeutics since its inception in December 2019. Michael has played a pivotal role in the company’s success, leading Treadwell to become a top player in the immuno-oncology space.

Michael Tusche has a Ph.D. in Immunology and Cancer Biology from the University of Toronto, an MBA in Business Administration and Management, General from the University of Toronto - Rotman School of Management, and a Bachelor of Science (B.Sc.) in Biochemistry and Microbiology from the University of Victoria.

Some individuals on their team include Tak Wah Mak - Co-Founder, Mark R. Bray - Co-Founder & Chief Scientific Officer, and Terry Shuai - CFO.